Reported 2 days ago
Novo Nordisk's stock plummeted by 33% after the company revised its full-year sales projections downward, primarily due to disappointing sales of its popular GLP-1 drugs, Ozempic and Wegovy. Rising competition from other firms offering tailored versions of these medications has also taken a toll. Despite these challenges, Novo Nordisk's stock is now trading at one of its lowest P/E ratios in decades, presenting a potential buying opportunity for long-term investors.
Source: YAHOO